Lynx Announces SNP Colaboration With Oxagen

July 1999
Worldwide Biotech;Jul99, Vol. 11 Issue 7, p5
Trade Publication
Reports that Lynx Therapeutics Inc. signed an agreement with Oxagen Limited regarding a program on the discovery and validation of disease-associated single nucleotide polymorphisms (SNP). Initial focus of the program; Separate tasks of Lynx and Oxagen; Designed uses of Lynx's SNP technologies; Reactions from the Lynx and Oxagen's chief executive officers.


Related Articles

  • WEEK IN REVIEW.  // BioWorld Insight;11/30/2009, Vol. 17 Issue 48, p5 

    The article offers world news briefs related to pharmaceutical companies. Antibody-drug conjugate collaboration of Seattle Genetics Inc. with Agensys Inc. have been expanded. BioCryst Pharmaceuticals Inc. priced 49 million dollars in their public stock offering. Novavax Inc. plans to raise their...

  • DANIOLABS/OXAGEN COLLABORATE ON INFLAMMATORY BOWEL DISEASE.  // Worldwide Biotech;Nov2003, Vol. 15 Issue 11, p2 

    Reports on the revenue-generating collaborative agreement in inflammatory bowel disease between DanioLabs Ltd. and Oxagen Ltd.

  • BASF invests $66 million in venture with U.S. firm. Rotman, David // Chemical Week;10/30/1996, Vol. 158 Issue 41, p18 

    Reports on BASF's agreement to form a joint venture with biotechnology firm Lynx Therapeutics of Hayward, California. BASF's investment in the new company to be called BASF-Lynx Bioscience; Lynx's development of gene sequencing technology that could simultaneously analyze the activity of all the...

  • ON THE MOVE.  // Pharmaceutical Technology Europe;Nov2003, Vol. 15 Issue 11, p72 

    Presents an update on key appointments. Appointment of Robert Misher as new chief operating officer of Almedica International; Recruitment of Mark Egerton as chief commercial officer of Oxagen; Selection of Gillian Walley as director of proposals and contracts of MDS Pharma Services; Appointment...

  • RECOMBINATION.  // Bio-IT World;Nov2003, Vol. 2 Issue 11, p20 

    Presents news on appointments and acquisitions within life sciences and pharmaceutical companies and related industries as of November 2003. Plan of GE Medical Systems to purchase Amersham PLC; Appointment of Mark Egerton as chief commercial officer and board member of Oxagen; Appointment of...

  • Leroy Hood. McCarthy, Kelly // Directors & Boards;Fall2000, Vol. 25 Issue 1, p58 

    Profiles Lynx Therapeutics board director Leroy Hood. Background in biotechnology; Career history; Views on business and science.

  • Lynx Launches Comparative Transciptome Study. Holland-Moritz, Pam // Genomics & Proteomics;May2003, Vol. 3 Issue 4, p15 

    Reports on Lynx Therapeutics Inc.'s agreement for a comparative transcriptome study with the Genome Institute of Singapore at the National University of Singapore. Application of Lynx's Massively Parallel Signature Sequencing technology to generate comprehensive gene expression profiles.

  • The Value of MPSS.  // Drug Discovery & Development;Jun2002, Vol. 5 Issue 6, p79 

    Discusses the value of massively parallel signature sequencing (MPSS) as a genomics technique for analyzing the expression of genes in a sample. MPSS as open-ended platform that counts the number of individual mRNA molecules produced from each gene; Systems biology experiments conducted by Lynx...

  • When opportunity knocks. Gopal, Kevin // Pharmaceutical Executive;Oct97, Vol. 17 Issue 10, p42 

    Reports on James Noble's resignation from British Biotech to become a part-time executive director of Oxagen, the first genomics company in Great Britain. Position held in British Biotech; Career background; Responsibilities as part-time executive director of Oxagen.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics